Showing results (191-200 of 525) with videos related to
Sort By:
Pageof 53
Lymphology|February 9, 1999
Levels of eicosanoids (6-oxo-PGF1 alpha and 8-epi-PGF2 alpha) in human and porcine lymphatics and lymphA Oguogho, J Kaliman, H SinzingerKlinische Wochenschrift|September 1, 1988
[Prevalence of plasma factor deficiency in the Vienna population. Results of a screening study of 1,300 adults]H Sinzinger, J Flores, F RauschaThe Journal of International Medical Research|January 1, 1988
Platelet deposition on human atherosclerotic lesions is decreased by low-dose aspirin in combination with dipyridamoleH Sinzinger, J O'Grady, P FitschaEuropean Journal of Nuclear Medicine|September 2, 1998
Adsorption of technetium-99m tetrofosmin and technetium-99m furifosmin on plastic syringesR Bartosch, S Granegger, H SinzingerLymphology|October 6, 1997
Isoprostane 8-epi-prostaglandin F2 alpha is a potent contractor of human peripheral lymphaticsH Sinzinger, A Oguogho, J KalimanProstaglandins|June 1, 1987
Prostaglandin I2 during radiolabelling improves recovery, but does not change platelet half-life and platelet uptake over active human lesion sitesH Sinzinger, P Fitscha, J KalimanNephron|January 1, 1995
Folic acid supplementation improves erythropoietin responseW Pronai, M Riegler-Keil, K Silberbauer, et al.Clinical Nephrology|October 1, 1987
Renin-angiotensin-aldosterone system and vasopressin in cyclosporine-treated renal allograft recipientsB Stanek, J Kovarik, S Rasoul-Rockenschaub, et al.Angiology|February 1, 1986
Platelet half-life, plasma thromboxane B2 and circulating endothelial-cells in peripheral vascular diseaseH Sinzinger, P Fitscha, B A PeskarProstaglandins & Other Lipid Mediators|July 14, 1998
Do E-series prostaglandins and their metabolites influence oxidation of native and glycated low-density lipoproteins?G Sobal, J E Menzel, H SinzingerPageof 53